362 related articles for article (PubMed ID: 29242299)
21. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).
Brunet S; Martino R; Sierra J
Curr Opin Oncol; 2013 Mar; 25(2):195-204. PubMed ID: 23385863
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
25. Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Wakita S; Kanamori H; Usuki K; Uoshima N; Yanada M; Shono K; Ueki T; Mizuno I; Yano S; Takeuchi J; Kanda J; Okamura H; Inamoto Y; Inokuchi K; Fukuda T
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1125-1132. PubMed ID: 27040395
[TBL] [Abstract][Full Text] [Related]
26. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
27. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia.
Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A
Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
29. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M; Brunet S; Nomdedéu J; Ribera JM; Tormo M; Duarte R; Escoda L; Guàrdia R; Queipo de Llano MP; Salamero O; Bargay J; Pedro C; Martí JM; Torrebadell M; Díaz-Beyá M; Camós M; Colomer D; Hoyos M; Sierra J; Esteve J;
Blood; 2013 Apr; 121(14):2734-8. PubMed ID: 23377436
[TBL] [Abstract][Full Text] [Related]
30. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
Deol A; Sengsayadeth S; Ahn KW; Wang HL; Aljurf M; Antin JH; Battiwalla M; Bornhauser M; Cahn JY; Camitta B; Chen YB; Cutler CS; Gale RP; Ganguly S; Hamadani M; Inamoto Y; Jagasia M; Kamble R; Koreth J; Lazarus HM; Liesveld J; Litzow MR; Marks DI; Nishihori T; Olsson RF; Reshef R; Rowe JM; Saad AA; Sabloff M; Schouten HC; Shea TC; Soiffer RJ; Uy GL; Waller EK; Wiernik PH; Wirk B; Woolfrey AE; Bunjes D; Devine S; de Lima M; Sandmaier BM; Weisdorf D; Khoury HJ; Saber W
Cancer; 2016 Oct; 122(19):3005-3014. PubMed ID: 27315441
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
32. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
33. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
34. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
35. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
[TBL] [Abstract][Full Text] [Related]
36. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with
Bazarbachi A; Bug G; Baron F; Brissot E; Ciceri F; Dalle IA; Döhner H; Esteve J; Floisand Y; Giebel S; Gilleece M; Gorin NC; Jabbour E; Aljurf M; Kantarjian H; Kharfan-Dabaja M; Labopin M; Lanza F; Malard F; Peric Z; Prebet T; Ravandi F; Ruggeri A; Sanz J; Schmid C; Shouval R; Spyridonidis A; Versluis J; Vey N; Savani BN; Nagler A; Mohty M
Haematologica; 2020 Jun; 105(6):1507-1516. PubMed ID: 32241850
[TBL] [Abstract][Full Text] [Related]
37. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
Canaani J; Labopin M; Socié G; Nihtinen A; Huynh A; Cornelissen J; Deconinck E; Gedde-Dahl T; Forcade E; Chevallier P; Bourhis JH; Blaise D; Mohty M; Nagler A
Am J Hematol; 2017 Jul; 92(7):653-659. PubMed ID: 28370339
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Metzelder SK; Schroeder T; Lübbert M; Ditschkowski M; Götze K; Scholl S; Meyer RG; Dreger P; Basara N; Fey MF; Salih HR; Finck A; Pabst T; Giagounidis A; Kobbe G; Wollmer E; Finke J; Neubauer A; Burchert A
Eur J Cancer; 2017 Nov; 86():233-239. PubMed ID: 29055209
[TBL] [Abstract][Full Text] [Related]
40. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.
Grunwald MR; Tseng LH; Lin MT; Pratz KW; Eshleman JR; Levis MJ; Gocke CD
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1989-95. PubMed ID: 25240816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
